We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

XBP:NASDAQXBP Global Holdings, Inc. Analysis

Data as of 2026-06-05 - not real-time

$2.16

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Technical outlook: The stock trades at $2.16, just above the identified support level of $2 but well below the 20‑day SMA of 2.42 and the 50‑day SMA of 2.90. Momentum indicators are weak – RSI sits at 35 (near‑oversold) and the MACD histogram is only marginally positive, signaling a tentative bullish crossover that lacks conviction. Volatility is extreme at 91.5% over the past 30 days and beta is slightly above market at 1.10, underscoring a high‑risk price profile.
Fundamental outlook: Revenue slipped 0.8% year‑over‑year to $791 M, with Q1 FY2026 down 14.2% YoY, while margins remain thin (gross margin 21.7%, operating margin –2.6%). The company is loss‑making (trailing EPS –$2.95) and cash‑flow negative, carrying a massive debt load of $431 M (debt‑to‑equity > 490). Valuation multiples are ultra‑low (PE ≈ 1, PB ≈ 0.29) and the market cap is only $25 M, suggesting a “price‑floor” scenario but also reflecting severe financial distress. Recent news highlights an AI‑led strategic pivot and the exploration of strategic alternatives, which could unlock upside if execution improves. Overall, the stock appears deeply discounted yet fraught with operational and liquidity challenges.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Price below short‑term moving averages and near support
  • Negative earnings, cash‑flow and high debt burden
  • Extreme volatility and thin trading volume

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Potential upside from AI‑driven product rollout
  • Exploration of strategic alternatives could improve capital structure
  • Valuation still offers significant upside if fundamentals stabilize

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Long‑run recovery hinges on successful AI transition and cost discipline
  • Debt reduction and cash‑flow generation remain critical
  • Market perception may improve if strategic alternatives are executed

Key Metrics & Analysis

Financial Health

Revenue Growth-0.80%
Profit Margin139.50%
P/E Ratio1.0
ROA0.74%
Debt/Equity493.70
P/B Ratio0.3
Op. Cash Flow$-141710000
Free Cash Flow$-171460000
Industry P/E33.9

Technical Analysis

TrendBearish
RSI35.2
Support$2.00
Resistance$3.00
MA 20$2.42
MA 50$2.90
MA 200$5.83
MACDBullish
VolumeStable
Fear & Greed Index93

Valuation

Target Price$5.00
Upside/Downside131.47%
GradeUndervalued
TypeBlend

Risk Assessment

Beta1.10
Volatility91.51%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.